Carperitide Is Associated With Increased In-Hospital Mortality in Acute Heart Failure: A Propensity Score-Matched Analysis. Matsue, Y., Kagiyama, N., Yoshida, K., Kume, T., Okura, H., Suzuki, M., Matsumura, A., Yoshida, K., & Hashimoto, Y. Journal of Cardiac Failure, 21(11):859--864, November, 2015. doi abstract bibtex BACKGROUND: Carperitide (α-human A-type natriuretic peptide) has been used for more than one-half of all acute heart failure (AHF) patients in Japan. However, its clinical effectiveness is not well documented. METHODS: We retrospectively identified AHF patients presenting with acute onset or worsening of symptoms and admitted to 1 of the 3 participating hospitals. Propensity score-matched analysis was performed. The primary end point was in-hospital mortality. RESULTS: Of all of the AHF patients included in this study, 402 (38.7%) were treated with carperitide, and in-hospital mortality rate for the total cohort was 7.6%. We matched 367 pairs of patients treated with and without carperitide according to propensity score. In this matched cohort, treatment with carperitide was associated with in-hospital mortality (odds ratio [OR] 2.13, 95% confidence interval [CI] 1.17-3.85; P = .013). Potentially more harmful effects were observed in elderly patients (OR 2.93, 95% CI 1.54-5.91). CONCLUSIONS: Carperitide was significantly associated with increased in-hospital mortality rate in AHF patients. Our results strongly suggest the necessity for well designed randomized clinical trials of carperitide to determine its clinical safety and effectiveness.
@article{matsue_carperitide_2015,
title = {Carperitide {Is} {Associated} {With} {Increased} {In}-{Hospital} {Mortality} in {Acute} {Heart} {Failure}: {A} {Propensity} {Score}-{Matched} {Analysis}},
volume = {21},
issn = {1532-8414},
shorttitle = {Carperitide {Is} {Associated} {With} {Increased} {In}-{Hospital} {Mortality} in {Acute} {Heart} {Failure}},
doi = {10.1016/j.cardfail.2015.05.007},
abstract = {BACKGROUND: Carperitide (α-human A-type natriuretic peptide) has been used for more than one-half of all acute heart failure (AHF) patients in Japan. However, its clinical effectiveness is not well documented.
METHODS: We retrospectively identified AHF patients presenting with acute onset or worsening of symptoms and admitted to 1 of the 3 participating hospitals. Propensity score-matched analysis was performed. The primary end point was in-hospital mortality.
RESULTS: Of all of the AHF patients included in this study, 402 (38.7\%) were treated with carperitide, and in-hospital mortality rate for the total cohort was 7.6\%. We matched 367 pairs of patients treated with and without carperitide according to propensity score. In this matched cohort, treatment with carperitide was associated with in-hospital mortality (odds ratio [OR] 2.13, 95\% confidence interval [CI] 1.17-3.85; P = .013). Potentially more harmful effects were observed in elderly patients (OR 2.93, 95\% CI 1.54-5.91).
CONCLUSIONS: Carperitide was significantly associated with increased in-hospital mortality rate in AHF patients. Our results strongly suggest the necessity for well designed randomized clinical trials of carperitide to determine its clinical safety and effectiveness.},
language = {eng},
number = {11},
journal = {Journal of Cardiac Failure},
author = {Matsue, Yuya and Kagiyama, Nobuyuki and Yoshida, Kazuki and Kume, Teruyoshi and Okura, Hiroyuki and Suzuki, Makoto and Matsumura, Akihiko and Yoshida, Kiyoshi and Hashimoto, Yuji},
month = nov,
year = {2015},
pmid = {25999241},
keywords = {Acute heart failure, Drug Therapy, Prognosis, vasodilator},
pages = {859--864}
}
Downloads: 0
{"_id":"mLA7j2fNfkjJ96R9y","bibbaseid":"matsue-kagiyama-yoshida-kume-okura-suzuki-matsumura-yoshida-etal-carperitideisassociatedwithincreasedinhospitalmortalityinacuteheartfailureapropensityscorematchedanalysis-2015","downloads":0,"creationDate":"2017-09-21T01:29:59.573Z","title":"Carperitide Is Associated With Increased In-Hospital Mortality in Acute Heart Failure: A Propensity Score-Matched Analysis","author_short":["Matsue, Y.","Kagiyama, N.","Yoshida, K.","Kume, T.","Okura, H.","Suzuki, M.","Matsumura, A.","Yoshida, K.","Hashimoto, Y."],"year":2015,"bibtype":"article","biburl":"https://api.zotero.org/users/465291/collections/IRKUUVWE/items?key=hwstUZQWv5PeUDo1dlxNM0pT&format=bibtex&limit=100","bibdata":{"bibtype":"article","type":"article","title":"Carperitide Is Associated With Increased In-Hospital Mortality in Acute Heart Failure: A Propensity Score-Matched Analysis","volume":"21","issn":"1532-8414","shorttitle":"Carperitide Is Associated With Increased In-Hospital Mortality in Acute Heart Failure","doi":"10.1016/j.cardfail.2015.05.007","abstract":"BACKGROUND: Carperitide (α-human A-type natriuretic peptide) has been used for more than one-half of all acute heart failure (AHF) patients in Japan. However, its clinical effectiveness is not well documented. METHODS: We retrospectively identified AHF patients presenting with acute onset or worsening of symptoms and admitted to 1 of the 3 participating hospitals. Propensity score-matched analysis was performed. The primary end point was in-hospital mortality. RESULTS: Of all of the AHF patients included in this study, 402 (38.7%) were treated with carperitide, and in-hospital mortality rate for the total cohort was 7.6%. We matched 367 pairs of patients treated with and without carperitide according to propensity score. In this matched cohort, treatment with carperitide was associated with in-hospital mortality (odds ratio [OR] 2.13, 95% confidence interval [CI] 1.17-3.85; P = .013). Potentially more harmful effects were observed in elderly patients (OR 2.93, 95% CI 1.54-5.91). CONCLUSIONS: Carperitide was significantly associated with increased in-hospital mortality rate in AHF patients. Our results strongly suggest the necessity for well designed randomized clinical trials of carperitide to determine its clinical safety and effectiveness.","language":"eng","number":"11","journal":"Journal of Cardiac Failure","author":[{"propositions":[],"lastnames":["Matsue"],"firstnames":["Yuya"],"suffixes":[]},{"propositions":[],"lastnames":["Kagiyama"],"firstnames":["Nobuyuki"],"suffixes":[]},{"propositions":[],"lastnames":["Yoshida"],"firstnames":["Kazuki"],"suffixes":[]},{"propositions":[],"lastnames":["Kume"],"firstnames":["Teruyoshi"],"suffixes":[]},{"propositions":[],"lastnames":["Okura"],"firstnames":["Hiroyuki"],"suffixes":[]},{"propositions":[],"lastnames":["Suzuki"],"firstnames":["Makoto"],"suffixes":[]},{"propositions":[],"lastnames":["Matsumura"],"firstnames":["Akihiko"],"suffixes":[]},{"propositions":[],"lastnames":["Yoshida"],"firstnames":["Kiyoshi"],"suffixes":[]},{"propositions":[],"lastnames":["Hashimoto"],"firstnames":["Yuji"],"suffixes":[]}],"month":"November","year":"2015","pmid":"25999241","keywords":"Acute heart failure, Drug Therapy, Prognosis, vasodilator","pages":"859--864","bibtex":"@article{matsue_carperitide_2015,\n\ttitle = {Carperitide {Is} {Associated} {With} {Increased} {In}-{Hospital} {Mortality} in {Acute} {Heart} {Failure}: {A} {Propensity} {Score}-{Matched} {Analysis}},\n\tvolume = {21},\n\tissn = {1532-8414},\n\tshorttitle = {Carperitide {Is} {Associated} {With} {Increased} {In}-{Hospital} {Mortality} in {Acute} {Heart} {Failure}},\n\tdoi = {10.1016/j.cardfail.2015.05.007},\n\tabstract = {BACKGROUND: Carperitide (α-human A-type natriuretic peptide) has been used for more than one-half of all acute heart failure (AHF) patients in Japan. However, its clinical effectiveness is not well documented.\nMETHODS: We retrospectively identified AHF patients presenting with acute onset or worsening of symptoms and admitted to 1 of the 3 participating hospitals. Propensity score-matched analysis was performed. The primary end point was in-hospital mortality.\nRESULTS: Of all of the AHF patients included in this study, 402 (38.7\\%) were treated with carperitide, and in-hospital mortality rate for the total cohort was 7.6\\%. We matched 367 pairs of patients treated with and without carperitide according to propensity score. In this matched cohort, treatment with carperitide was associated with in-hospital mortality (odds ratio [OR] 2.13, 95\\% confidence interval [CI] 1.17-3.85; P = .013). Potentially more harmful effects were observed in elderly patients (OR 2.93, 95\\% CI 1.54-5.91).\nCONCLUSIONS: Carperitide was significantly associated with increased in-hospital mortality rate in AHF patients. Our results strongly suggest the necessity for well designed randomized clinical trials of carperitide to determine its clinical safety and effectiveness.},\n\tlanguage = {eng},\n\tnumber = {11},\n\tjournal = {Journal of Cardiac Failure},\n\tauthor = {Matsue, Yuya and Kagiyama, Nobuyuki and Yoshida, Kazuki and Kume, Teruyoshi and Okura, Hiroyuki and Suzuki, Makoto and Matsumura, Akihiko and Yoshida, Kiyoshi and Hashimoto, Yuji},\n\tmonth = nov,\n\tyear = {2015},\n\tpmid = {25999241},\n\tkeywords = {Acute heart failure, Drug Therapy, Prognosis, vasodilator},\n\tpages = {859--864}\n}\n\n","author_short":["Matsue, Y.","Kagiyama, N.","Yoshida, K.","Kume, T.","Okura, H.","Suzuki, M.","Matsumura, A.","Yoshida, K.","Hashimoto, Y."],"key":"matsue_carperitide_2015","id":"matsue_carperitide_2015","bibbaseid":"matsue-kagiyama-yoshida-kume-okura-suzuki-matsumura-yoshida-etal-carperitideisassociatedwithincreasedinhospitalmortalityinacuteheartfailureapropensityscorematchedanalysis-2015","role":"author","urls":{},"keyword":["Acute heart failure","Drug Therapy","Prognosis","vasodilator"],"downloads":0},"search_terms":["carperitide","associated","increased","hospital","mortality","acute","heart","failure","propensity","score","matched","analysis","matsue","kagiyama","yoshida","kume","okura","suzuki","matsumura","yoshida","hashimoto"],"keywords":["acute heart failure","drug therapy","prognosis","vasodilator"],"authorIDs":[],"dataSources":["TML33E22xSRKFfezh"]}